Glioblastoma (GBM) is one of the deadliest types of cancer and highly refractory to
chemoradiation and immunotherapy. One of the main reasons for this resistance to therapy …

Phenotypic plasticity has emerged as a major contributor to intra-tumoral heterogeneity and
treatment resistance in cancer. Increasing evidence shows that glioblastoma (GBM) cells …

Single-cell RNA sequencing has revealed extensive transcriptional cell state diversity in
cancer, often observed independently of genetic heterogeneity, raising the central question …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

Glioblastoma (GBM) tumors consist of multiple cell populations, including self-renewing
glioblastoma stem cells (GSCs) and immunosuppressive microglia. Here we identified …

Bulk sequencing methodologies have allowed us to make great progress in cancer
research. Unfortunately, these techniques lack the resolution to fully unravel the epigenetic …

Brain cancers carry bleak prognoses, with therapeutic advances hel** only a minority of
patients over the past decade. The brain tumour microenvironment (TME) is highly …

Glioblastoma (GBM) is a highly lethal type of cancer. GBM recurrence following
chemoradiation is typically attributed to the regrowth of invasive and resistant cells …

In the past decade, remarkable progress in cancer medicine has been achieved by the
development of treatments that target DNA sequence variants. However, a purely genetic …

In 2021, the World Health Organization reclassified glioblastoma, the most common form of
adult brain cancer, into isocitrate dehydrogenase (IDH)-wild-type glioblastomas and grade …